La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Marksans Pharma Résultats passés
Passé contrôle des critères 5/6
Marksans Pharma has been growing earnings at an average annual rate of 21.2%, while the Pharmaceuticals industry saw earnings growing at 15.4% annually. Revenues have been growing at an average rate of 15.9% per year. Marksans Pharma's return on equity is 16%, and it has net margins of 14.7%.
Informations clés
21.2%
Taux de croissance des bénéfices
19.3%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 17.5% |
| Taux de croissance des recettes | 15.9% |
| Rendement des fonds propres | 16.0% |
| Marge nette | 14.7% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Jul 28
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Nov 04If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Oct 20Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?
Oct 05If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns
Sep 20Ventilation des recettes et des dépenses
Comment Marksans Pharma gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 22,680 | 3,338 | 3,059 | 0 |
| 31 Mar 24 | 21,774 | 3,137 | 2,936 | 0 |
| 31 Dec 23 | 21,034 | 3,164 | 2,875 | 0 |
| 30 Sep 23 | 19,971 | 2,965 | 2,752 | 0 |
| 30 Jun 23 | 19,184 | 2,743 | 2,637 | 0 |
| 31 Mar 23 | 18,521 | 2,653 | 2,521 | 0 |
| 31 Dec 22 | 17,842 | 2,123 | 2,436 | 0 |
| 30 Sep 22 | 16,670 | 2,004 | 2,375 | 0 |
| 30 Jun 22 | 15,756 | 1,847 | 2,326 | 0 |
| 31 Mar 22 | 14,908 | 1,868 | 2,250 | 0 |
| 31 Dec 21 | 14,069 | 2,367 | 2,351 | 0 |
| 30 Sep 21 | 14,026 | 2,473 | 2,269 | 0 |
| 30 Jun 21 | 14,064 | 2,518 | 2,037 | 0 |
| 31 Mar 21 | 13,762 | 2,385 | 2,096 | 0 |
| 31 Dec 20 | 13,817 | 2,018 | 1,908 | 0 |
| 30 Sep 20 | 13,142 | 1,724 | 1,833 | 0 |
| 30 Jun 20 | 12,203 | 1,476 | 1,700 | 0 |
| 31 Mar 20 | 11,344 | 1,208 | 1,785 | 0 |
| 31 Dec 19 | 10,463 | 879 | 1,719 | 0 |
| 30 Sep 19 | 9,972 | 834 | 1,677 | 0 |
| 30 Jun 19 | 10,099 | 780 | 1,631 | 0 |
| 31 Mar 19 | 10,001 | 804 | 1,659 | 0 |
| 31 Dec 18 | 9,523 | 666 | 1,601 | 0 |
| 30 Sep 18 | 9,223 | 582 | 1,599 | 0 |
| 30 Jun 18 | 9,272 | 463 | 1,474 | 0 |
| 31 Mar 18 | 9,127 | 358 | 1,534 | 0 |
| 31 Dec 17 | 8,918 | 343 | 1,528 | 0 |
| 30 Sep 17 | 8,949 | 275 | 1,550 | 0 |
| 30 Jun 17 | 8,015 | 187 | 1,492 | 0 |
| 31 Mar 17 | 7,672 | 113 | 1,547 | 0 |
| 31 Dec 16 | 7,926 | 70 | 1,475 | 0 |
| 30 Sep 16 | 7,948 | 136 | 1,458 | 0 |
| 30 Jun 16 | 8,699 | 481 | 1,424 | 0 |
| 31 Mar 16 | 8,933 | 785 | 1,270 | 0 |
| 31 Dec 15 | 8,536 | 1,093 | 1,585 | 0 |
| 30 Sep 15 | 8,495 | 1,191 | 1,397 | 0 |
| 30 Jun 15 | 8,045 | 1,154 | 728 | 0 |
| 31 Mar 15 | 7,967 | 1,094 | 758 | 0 |
| 31 Dec 14 | 7,850 | 950 | 1,482 | 0 |
| 30 Sep 14 | 7,405 | 897 | 1,121 | 0 |
| 30 Jun 14 | 6,914 | 786 | 693 | 0 |
| 31 Mar 14 | 6,300 | 719 | 1,091 | 0 |
| 31 Dec 13 | 5,950 | 1,020 | 1,013 | 0 |
| 30 Sep 13 | 5,406 | 877 | 994 | 0 |
Des revenus de qualité: MARKSANS a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: MARKSANS's current net profit margins (14.7%) are higher than last year (14.3%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: MARKSANS's earnings have grown significantly by 21.2% per year over the past 5 years.
Accélération de la croissance: La croissance des bénéfices de MARKSANS au cours de l'année écoulée ( 21.7% ) dépasse sa moyenne sur 5 ans ( 21.2% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices MARKSANS au cours de l'année écoulée ( 21.7% ) a dépassé celle du secteur Pharmaceuticals 18.9%.
Rendement des fonds propres
ROE élevé: MARKSANS's Return on Equity (16%) is considered low.